
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform that has shown success in delivering therapeutics to a broad range of target tissues. With the completion of recruitment in the 10mg/kg multi-dose cohort in the FREEDOM2 study of PGN-EDODM1 and the maintenance of data readout timing, PEPG is on track for a potential commercial launch in the US in FY30. Despite potential delays with the partial clinical hold, the company has a strong financial position with $132M in cash/equivalents. With encouraging drug concentrations and improved safety measures observed in preclinical studies, and the potential for emerging competitors in the field, PEPG remains a promising investment opportunity with an adjusted target of $4 per share.
Bears say
PepGen is currently facing several challenges ranging from financial constraints to complex clinical results. The company's recent 1Q26 financial results were below consensus, and their reliance on external funding to advance their drug development platform may result in delays. Additionally, the results from their FREEDOM-2 study are difficult to interpret and warrant further analysis. The company's target price has been lowered, and they may face challenges in gaining regulatory approval without certain features in their product label.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares